WO2010100179A3 - Self-forming gel system for sustained drug delivery - Google Patents

Self-forming gel system for sustained drug delivery Download PDF

Info

Publication number
WO2010100179A3
WO2010100179A3 PCT/EP2010/052665 EP2010052665W WO2010100179A3 WO 2010100179 A3 WO2010100179 A3 WO 2010100179A3 EP 2010052665 W EP2010052665 W EP 2010052665W WO 2010100179 A3 WO2010100179 A3 WO 2010100179A3
Authority
WO
WIPO (PCT)
Prior art keywords
self
drug delivery
gel system
sustained drug
forming gel
Prior art date
Application number
PCT/EP2010/052665
Other languages
French (fr)
Other versions
WO2010100179A2 (en
Inventor
Bhas A. Dani
Lorenz Meinel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2010100179A2 publication Critical patent/WO2010100179A2/en
Publication of WO2010100179A3 publication Critical patent/WO2010100179A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Antibody formulations, and methods for their manufacture, which (i) are capable of preserving an antibody in a native and therapeutically active state while achieving a depot effect without the use of polymers or other complex formulation, reagents and (ii) provide very high loading capacity, thus offering the potential for increased dose per application to patient. These formulations take the form of a gel and are based on the surprising finding that some monoclonal antibodies have a gelation property under appropriate conditions.
PCT/EP2010/052665 2009-03-05 2010-03-03 Self-forming gel system for sustained drug delivery WO2010100179A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15766809P 2009-03-05 2009-03-05
US61/157,668 2009-03-05

Publications (2)

Publication Number Publication Date
WO2010100179A2 WO2010100179A2 (en) 2010-09-10
WO2010100179A3 true WO2010100179A3 (en) 2011-05-12

Family

ID=42308555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/052665 WO2010100179A2 (en) 2009-03-05 2010-03-03 Self-forming gel system for sustained drug delivery

Country Status (1)

Country Link
WO (1) WO2010100179A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
US9352043B2 (en) 2010-05-14 2016-05-31 Amgen Inc. High concentration antibody formulations

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350454T3 (en) 1998-11-27 2011-01-24 Ucb Pharma S.A. COMPOSITIONS AND METHODS TO INCREASE THE MINERALIZATION OF THE BONE SUBSTANCE.
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (en) 2007-09-17 2008-11-07 Amgen Inc Use of a sclerostin binding agent to inhibit bone resorption.
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102844033A (en) * 2010-04-16 2012-12-26 诺华有限公司 Methods and compositions for improving implant osseointegration
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP2688910B1 (en) 2011-03-25 2019-05-29 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
LT2699261T (en) 2011-04-19 2018-11-12 Amgen Inc. Method for treating osteoporosis
PL2739311T3 (en) 2011-08-04 2018-08-31 Amgen Inc. Method for treating bone gap defects
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
EP2869844B2 (en) 2012-07-05 2023-06-21 UCB Pharma S.A. Treatment for bone diseases
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
MA41142A (en) 2014-12-12 2017-10-17 Amgen Inc ANTI-SCLEROSTINE ANTIBODIES AND THE USE OF THEM TO TREAT BONE CONDITIONS AS PART OF THE TREATMENT PROTOCOL
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
MA45921A (en) 2016-08-08 2019-06-19 Amgen Inc METHOD OF IMPROVING CONNECTIVE TISSUE FIXATION USING ANTI-SCLEROSTINE ANTIBODIES.
JP2020528411A (en) * 2017-07-27 2020-09-24 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． SOST antibody pharmaceutical composition and its use
CN112166120A (en) 2018-03-30 2021-01-01 安姆根有限公司 C-terminal antibody variants
WO2020033788A1 (en) 2018-08-10 2020-02-13 Amgen Inc. Method of preparing an antibody pharmaceutical formulation
US20220275073A1 (en) 2019-08-12 2022-09-01 Amgen Inc. Anti-Sclerostin Antibody Formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071394A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071394A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARN N ET AL: "Highly concentrated monoclonal antibody solutions: Direct analysis of physical structure and thermal stability", JOURNAL OF PHARMACEUTICAL SCIENCES 200703 US LNKD- DOI:10.1002/JPS.20753, vol. 96, no. 3, March 2007 (2007-03-01), pages 532 - 546, XP002626716, ISSN: 0022-3549 *
LIU JUN ET AL: "Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 9, 1 September 2005 (2005-09-01), pages 1928 - 1940, XP002578902, ISSN: 0022-3549, [retrieved on 20050728], DOI: DOI:10.1002/JPS.20347 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9352043B2 (en) 2010-05-14 2016-05-31 Amgen Inc. High concentration antibody formulations
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents

Also Published As

Publication number Publication date
WO2010100179A2 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
WO2010100179A3 (en) Self-forming gel system for sustained drug delivery
TN2009000382A1 (en) Stable antibody formulations
WO2011109365A3 (en) Concentrated protein formulations and uses thereof
TN2011000229A1 (en) Antibody formulation
CR20210035A (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
WO2019094395A3 (en) Hydrophilic linkers for antibody drug conjugates
WO2017044894A3 (en) Cartilage-homing peptides
WO2011085158A3 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
EP3409289A3 (en) Stable antibody containing compositions
WO2019060425A8 (en) Compositions for chimeric antigen receptor t cell therapy and uses thereof
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
WO2008103409A3 (en) Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis
GB2465532B (en) Absorbable adhesives and their formulation for use in medical applications
MX364396B (en) Modified poly(beta-amino ester)s for drug delivery.
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
MY164610A (en) Stabilized formulations containing anti-ngf antibodies
WO2012076670A3 (en) Antibody formulation
MX2012012668A (en) High shear application in drug delivery.
NZ612326A (en) Biodegradable drug delivery compositions
WO2015058173A8 (en) Stable solid units and methods of making the same
WO2011163651A3 (en) METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
WO2011116026A3 (en) Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2011071280A3 (en) Intracelluar targeting bipodal peptide binder
WO2013039621A3 (en) Methods and systems for making microtablets for drug delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10705893

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10705893

Country of ref document: EP

Kind code of ref document: A2